Biogen’s controversial Alzheimer’s drug generates $2 million sales in first few weeks after approval

Biogen’s controversial Alzheimer’s drug generates million sales in first few weeks after approval
Biogen’s Alzheimer’s drug, Aduhelm, generated $ 2 million in revenue in the first few weeks of its approval, the company said in its second-quarter earnings.

Earnings